ClinicalTrials.gg
CompletedNCT02497287SUSTAIN-2Updated Apr 29, 2025Results posted

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

A Phase 3 interventional study of Esketamine (Intranasal Spray) and Duloxetine (Oral Antidepressant) in Treatment-resistant Depression, sponsored by Janssen Research & Development, LLC. Completed at 110 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
802
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant — 4 open to participants now, 4 under way, 2 of them phase 3. Esketamine · Depressive Disorder, Treatment-Resistant.

Enrollment
2nd of 18
802 · median 210
Started
2015
with 4 others
Phase 3
11 of 18
2 open now
Registered
7th of 18
by date
Lead sponsor
11 of 18
Janssen Research & Development, LLC

Among the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant, this one is the 2nd largest by enrollment, is one of 5 that started in 2015, is one of 11 in phase 3, and was the 7th registered.

Depressive Disorder, Treatment-Resistant

448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

4 of the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About esketamine

Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant, or all of them as a file.
02

Study summary

The purpose of this open-label, multicenter study is to assess the long term safety and efficacy of intranasal esketamine plus an oral antidepressant in participants with treatment-resistant depression (TRD).

Read the detailed description

This is an open-label (the researchers and participants know the treatment the participant is receiving), multicenter (more than 1 study site), long-term safety and efficacy study of intranasal esketamine plus an oral antidepressant in participants with treatment-resistant depression (TRD). Participants will enter the study either directly (direct-entry participants) or after completing the Double-Blind Induction Phase of ESKETINTRD3005 (transferred-entry participants). The study consists of 4 phases: Screening Phase (4 weeks), Open-Label Induction Phase (4 weeks), Open-Label Optimization/Maintenance phase (48 weeks), and Follow up Phase (4 weeks). Transferred entry non-responders in the ESKETINTRD3005 may enter study at the Open-Label Induction Phase and responders in the ESKETINTRD3005 may enter Optimization/Maintenance phase. In the Open-Label Induction Phase, participants will self-administer flexibly-dosed intranasal esketamine (participants who are less than (\<) 65 years old self-administer 56 mg or 84 mg dose, participants who are greater than or equal to (>=) 65 years old self-administer 28 mg, 56 mg or 84 mg dose) twice weekly for 4 weeks. The starting dose for all participants >= 65 years old will be 28 mg. In addition, each direct-entry participants will be assigned to receive 1 of 4 selected oral antidepressant medications (escitalopram or sertraline or duloxetine or venlafaxine extended release [XR]), initiated on Day 1 of the open-label induction phase and continued through the duration of the study. Transferred-entry participants will continue their same antidepressant from ESKETINTRD3005 through the duration of this study. Participants who are responders at the end of the Open-Label Induction phase and transferred-entry responder participants (from study ESKETINTRD3005) will enter the Optimization/Maintenance Phase where intranasal esketamine treatment sessions will be reduced from that in the induction phase (twice weekly) to weekly for the first 4 weeks of this phase, and then individualized to either once weekly or once every other week based on the severity of depressive symptoms. Participants' safety and depressive symptoms will be assessed and monitored throughout the study.

03

Conditions studied

  • Treatment-resistant Depression

Keywords

  • Treatment-resistant Depression
  • Esketamine
  • Oral Antidepressant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A). For Direct-Entry Participants

  • At the time of signing the form (ICF), participant must be a man or woman ≥18 (or older if the minimum legal age of consent in the country in which the study is taking place is greater than [>]18)
  • At the start of the screening phase, participant must meet the (DSM-5) diagnostic criteria for single-episode major depressive disorder (MDD) (if single-episode MDD, the duration must be greater than or equal to [>=] 2 years) or recurrent MDD, without psychotic features, based upon clinical assessment and confirmed by the Mini-International Neuropsychiatric Interview (MINI)
  • At screening, participant must have a MADRS total score of >=22
  • At the start of the screening phase, participants must have had nonresponse to >=2 oral antidepressant treatments in the current episode of depression, as assessed using the the MGHATRQ and confirmed by documented records (example medical/pharmacy/prescription records or a letter from treating a physician, etc,) B). For Transferred-entry Participants
  • All participants who completed the double-blind induction phase of ESKETINTRD3005 study, regardless of their response status, will be eligible to participate in this study, if they meet the study specific eligibility criteria

Exclusion criteria

Exclusion Criteria:

A). For Direct-Entry Participants

  • Participant's depressive symptoms have previously not responded to: Esketamine or ketamine in the current major depressive episode per clinical judgment or All of the 4 oral antidepressant treatment options available in the respective country for the open-label induction phase (that is, duloxetine, escitalopram, sertraline, and venlafaxine XR) in the current major depressive episode (based on Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire [ MGH-ATRQ])
  • Participant has a current or prior diagnosis of a psychotic disorder or MDD with psychotic features, bipolar or related disorders (confirmed by the MINI), obsessive compulsive disorder (current only), intellectual disability (DSM-5 diagnostic codes 317, 318.0, 318.1, 318.2, 315.8, and 319), autism spectrum disorder, borderline personality disorder, antisocial personality disorder, histrionic personality disorder, or narcissistic personality disorder
  • Participant has homicidal ideation/intent, per the investigator's clinical judgment, or has suicidal ideation with some intent to act within 6 months prior to the start of the screening phase, per the investigator's clinical judgment or based on the Columbia Suicide Severity Rating Scale (C-SSRS)
  • Participants with history of moderate or severe substance or alcohol use disorder according to DSM-5 criteria
  • Participants who has a (MMSE) \<25; Has neurodegenerative disorder (example, Alzheimer's disease, vascular dementia, Parkinson's disease), or evidence of mild cognitive impairment (MCI) B). Transferred-Entry Participants
  • Participant has taken any prohibited therapies that would not permit dosing on Day 1
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
802 participants (actual)

Study arms

  • Experimental
    Intranasal Esketamine plus oral antidepressant

    Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg). Participants greater than or equal to (\>=) 65 will start at a dose of 28 mg on Day 1. Direct-entry participants will initiate a new, open-label oral antidepressant (duloxetine, escitalopram, sertraline, or venlafaxine extended release \[XR\]) on Day 1; transferred-entry participants will continue the same oral antidepressant from ESKETINTRD3005. Optimization/Maintenance Phase: Participants will self-administer esketamine (56mg or 84mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years) intranasally once per week for 4 weeks; transferred entry responder subjects from ESKETINTRD3005 will start at a dose of 28 mg in the first week. All participants will continue their same oral antidepressant during this phase.

    Drug: Esketamine (Intranasal Spray) · Drug: Duloxetine (Oral Antidepressant) · Drug: Escitalopram (Oral Antidepressant) · Drug: Sertraline (Oral Antidepressant) · Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)

Interventions

  • Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years). Participants \>= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants will self-administer esketamine intranasally (56 mg or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years) once weekly then individualized to either once weekly or once every other week based on the severity of depressive symptoms. Transferred-entry responder participants from ESKETINTRD3005 \>= 65 years old will start at a dose of 28 mg in Week 5.

  • Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).

  • Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. The minimum therapeutic dose is 10 mg/day. Participants \>= 65 years of age will be titrated up to 20 mg/day, but can lower the dose to 10 mg/day for tolerability.

  • Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.

  • Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated for participants \< 65 years of age up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day. For participants \>= 65, it can be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event is any untoward medical occurrence in a clinical study participants who administered a medicinal (investigational or non-investigational) product and does not necessarily have a causal relationship with the treatment. A TEAE defined as an event that was new in onset or increased in severity following treatment initiation.

    Time frame: Up to End of Follow up Phase (Week 56)

  2. Percentage of Participants With Cystitis, Urinary Tract Infections, Renal and Urinary Tract Symptoms, Renal and Urinary Disorders

    Percentage of participants with cystitis, urinary tract infections, renal and urinary tract symptoms, renal and urinary disorders were evaluated. Cystitis and urinary tract infections are selected MedDRA preferred terms, "renal and urinary tract symptoms" refers to any preferred term (PT) in the group of selected PTs; and "renal and urinary disorders" refers to a MedDRA System Organ Class (SOC).

    Time frame: Up to End of Follow up Phase (Week 56)

  3. Change From Baseline in Cognitive Test Battery: Detection Test (DET) Score

    This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. The DET is a measure of psychomotor function and uses a well-validated simple reaction time. In this outcome measure, speed of performance of participants (calculated as mean of the logarithmic base 10 transformed reaction times) for correct responses was reported. Total score ranges from 2 to 3.3 log 10 milliseconds (msec). Lower score indicates better performance. Higher change from baseline indicates better performance.

    Time frame: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of Optimization/Maintenance [OP/MA] Phase)

  4. Change From Baseline in Cognitive Test Battery: Identification Test (IDN) Score

    This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. IDN test is a measure of visual attention (choice reaction time) and scored for speed of response (mean of the log10 transformed reaction times for correct responses). Total score ranges from 2 to 3.3 log 10 msec. Lower score indicates better performance. Higher change from baseline indicates better performance.

    Time frame: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)

  5. Change From Baseline in Cognitive Test Battery: One Card Learning Test (OCL) Score

    This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. OCL test is a measure of visual episodic memory and visual recall test scored using arcsine transformation of the percentage of correct responses (CR). The range for OCL is 0 to 100 percent (%) accuracy; presented as an arcsin transformation, the range is 0 to 1.57. Higher score indicates better performance. Higher change from baseline indicates better performance.

    Time frame: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)

  6. Change From Baseline in Cognitive Test Battery: One Back Test (ONB) Score

    The ONB is a measure of working memory and scored for speed of correct response (mean of the log10-transformed reaction times for correct responses). Total score ranges from 2 to 3.54 log10 msec. Lower score indicates better performance. Higher change from baseline indicates better performance.

    Time frame: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)

  7. Change From Baseline in Cognitive Test Battery: Groton Maze Learning Test (GMLT) Score

    This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. GMLT measures executive function; maze/sequencing test, scored for total number of errors. Total score ranges from 0 to 999 number of errors. Lower score indicates better performance. Higher change from baseline indicates better performance.

    Time frame: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)

  8. Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Total Recall

    Hopkins Verbal Learning Test (HVLT) measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition.

    Time frame: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)

  9. Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Delayed Recall

    HVLT measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition.

    Time frame: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)

  10. Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Number of Words Recalled

    HVLT measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition.

    Time frame: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)

  11. Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Recognition Discrimination Index

    HVLT measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition.

    Time frame: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)

Secondary outcomes

  1. Change From Baseline to Endpoint in Montgomery Asberg Depression Rating Scale (MADRS) Total Score During Induction (IND) Phase

    MADRS measures depression severity, detects changes due to AD treatment. It consists 10 items (evaluate apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts), scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores indicate more severe condition. Negative change in score indicates improvement. Missing data was imputed using last observation carried forward (LOCF) method, last post baseline observation during the phase was carried forward as the "Endpoint".

    Time frame: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)

  2. Change From Baseline to Endpoint in MADRS Total Score During Optimization/Maintenance (OP/MA) Phase

    MADRS measure depression severity, detects changes due to AD treatment. It evaluates 10 items: apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

    Time frame: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)

  3. Change From Baseline to Endpoint in Patient Health Questionnaire - 9 (PHQ-9) Total Score During IND Phase

    PHQ-9 is a 9-item, self-reporting scale assessing depressive symptoms. Each item was rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day), with a total score range of 0-27. A higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), severe (20-27). The recall period is 2 weeks. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

    Time frame: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)

  4. Change From Baseline to Endpoint in PHQ-9 Total Score During OP/MA Phase

    PHQ-9 is a 9-item, self-reporting scale assessing depressive symptoms. Each item was rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day), with a total score range of 0-27. A higher score indicates greater severity of depression. severity of PHQ-9 categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), severe (20-27). The recall period is 2 weeks. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

    Time frame: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)

  5. Change From Baseline to Endpoint in Clinical Global Impression of Severity (CGI-S) Scale Score During IND Phase

    CGI-S measures severity of participant's illness that include knowledge of participant's history, psychosocial circumstances, symptoms, behavior, impact of symptoms on participant's ability to function. CGI-S evaluates severity of psychopathology on a scale range from 0 - 7, where 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as "Endpoint".

    Time frame: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)

  6. Change From Baseline to Endpoint in CGI-S Scale Score During OP/MA Phase

    The CGI-S measures the severity of the participant's illness that include knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7, where 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

    Time frame: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)

  7. Change From Baseline to Endpoint in Generalized Anxiety Disorder (GAD-7) Total Score During IND Phase

    GAD-7 is brief, validated 7-item self-reported assessment of overall anxiety. Participant's responded to each item using a 4 point scale with response categories: 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield total score ranges from 0 to 21, higher scores indicate more anxiety. Negative change in score indicates improvement. Severity of GAD-7 is categorized as: None (0-4), Mild (5-9), Moderate (10-14), Severe (15 -21). Missing data was imputed using LOCF method, last post baseline observation during the phase was carried forward as "Endpoint".

    Time frame: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)

  8. Change From Baseline to Endpoint in GAD-7 Total Score During OP/MA Phase

    GAD-7 is brief and validated 7-item self-reported assessment of overall anxiety. Participants respond to each item using a 4 point scale with response categories: 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score ranges from 0 to 21, higher scores indicate more anxiety. Negative change in score indicates improvement. Severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14), Severe (15 -21). Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

    Time frame: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)

  9. Change From Baseline to Endpoint in European Quality of Life (EuroQol) 5-Dimension, 5-Level (EQ 5D-5L) During IND Phase: Sum Score

    EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a Health Status Index (HSI). HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) \*5. Higher score indicates worst health state.

    Time frame: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)

  10. Change From Baseline to Endpoint in EQ-5D-5L Score During IND Phase: EQ-VAS

    EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine).

    Time frame: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)

  11. Change From Baseline to Endpoint in EQ-5D-5L Scale Score During IND Phase: Health Status Index

    EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a HSI. HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health).

    Time frame: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)

  12. Change From Baseline to Endpoint in European Quality of Life (EuroQol) 5-Dimension, 5-Level (EQ 5D-5L) During OP/MA Phase: Sum Score

    EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a Health Status Index (HSI). HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) \*5. Higher score indicates worst health state.

    Time frame: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)

  13. Change From Baseline to Endpoint in EQ-5D-5L Score During OP/MA Phase: EQ-VAS

    EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine).

    Time frame: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)

  14. Change From Baseline to Endpoint in EQ-5D-5L Scale Score During OP/MA Phase: Health Status Index

    EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a HSI. HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health).

    Time frame: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)

  15. Change From Baseline in Sheehan Disability Scale (SDS) Total Score During IND Phase

    SDS was a 5 item questionnaire used for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, (3) family life/home responsibilities using a 0 to 10 rating scale. Score for the first three items are summed to create a total score of 0 to 30, higher score indicates greater impairment and a negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

    Time frame: Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND Phase)

  16. Change From Baseline in Sheehan Disability Scale Total Score During OP/MA Phase

    SDS was a participant-reported outcome measure and was a 5 item questionnaire used for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0 to 10 rating scale. The score for the first three items are summed to create a total score of 0 to 30 where a higher score indicates greater impairment and a negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

    Time frame: Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)

  17. Percentage of Participants With Response as Assessed by MADRS Total Score During IND Phase

    Response is defined as greater than or equal to (\>=) 50 % reduction from baseline in the MADRS total score. MADRS measures depression severity, detects changes due to AD treatment. It consists 10 items (evaluate apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts), scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores indicate more severe condition. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

    Time frame: Days 8, 15, 22 and Endpoint (last post-baseline assessment during 4 weeks of IND phase)

  18. Percentage of Participants With Response as Assessed by PHQ-9 Total Score During IND Phase

    Response is defined as \>= 50 % reduction from baseline (IND phase) in PHQ-9 total score. PHQ-9 is a 9-item, self-reporting scale assessing depressive symptoms. Each item was rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day), with a total score range of 0-27. The scores are summed for a total score ranging from 0-27. A higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), severe (20-27). The recall period is 2 weeks. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

    Time frame: Day 15 and Endpoint (last post-baseline assessment value during 4 Week IND phase)

  19. Percentage of Participants With Remission as Assessed by MADRS Total Score During IND Phase

    Remission is defined as MADRS total score less than or equal to (\<=) 12. MADRS measures depression severity, detects changes due to AD treatment. It consists 10 items (evaluate apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts), scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores indicate more severe condition. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

    Time frame: Days 8, 15, 22 and Endpoint (last post-baseline assessment value during 4 weeks of IND Phase)

  20. Percentage of Participants With Remission as Assessed by PHQ-9 Total Score During IND Phase

    Remission is defined as PHQ-9 total score \<= 4. PHQ-9 is a 9-item, self-reporting scale assessing depressive symptoms. Each item was rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day), with a total score range of 0-27. The scores are summed for a total score ranging from 0-27. A higher score indicates greater severity of depression. severity of PHQ-9 categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), severe (20-27). The recall period is 2 weeks. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

    Time frame: Day 15 and Endpoint (last post-baseline assessment value during 4 weeks of IND phase)

  21. Percentage of Participants With an Increase Score From Predose at Any Time in Clinician-Administered Dissociative States Scale (CADSS) Total Score During IND Phase

    The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. It comprises 23 subjective items divided into 3 components: depersonalization (with score range from 0 to 28), derealization (with score range from 0 to 52), and amnesia (with score range from 0 to 8). Participants responses are coded on a 5-point scale (0 = "Not at all", 1 = "Mild", 2 = "Moderate", 3 = 'Severe" and 4 = "Extreme"). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition.

    Time frame: Predose, up to 1.5 hours postdose (up to end of IND phase [Week 4])

  22. Percentage of Participants With an Increase Score From Predose at Any Time in CADSS Total Score During OP/MA Phase

    The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. It comprises 23 subjective items divided into 3 components: depersonalization (with score range from 0 to 28), derealization (with score range from 0 to 52), and amnesia (with score range from 0 to 8). Participants responses are coded on a 5-point scale (0 = "Not at all", 1 = "Mild", 2 = "Moderate", 3 = 'Severe" and 4 = "Extreme"). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition.

    Time frame: Predose, up to 1.5 hours postdose (up to end of OP/MA phase [Week 52])

  23. Percentage of Participants With Treatment-Emergent Acute Hypertension (Systolic and Diastolic) During IND and OP/MA Phases

    Percentage of participants with treatment-emergent acute hypertension (Systolic Blood Pressure \>=180 millimeters of mercury \[mm Hg\] or Diastolic Blood Pressure \>= 110 mm Hg) during IND and OP/MA Phases were evaluated.

    Time frame: Up to End of OP/MA phase (Week 52)

07

Results

Posted Apr 29, 2019
Limitations and caveats
Protocol defined study will be completed when at least 300 participants reach 26 weeks and 100 reach 52 weeks of treatment with esketamine. Discontinuation due to "Study terminated by sponsor" reflects reaching these prespecified completion criteria.

Participant flow

In this study participants from study ESKETINTRD3005 (NCT02422186) were enrolled (transferred entry \[TE\]). ESKETINTRD3005 is referred as TRD3005 in the draft.

Induction Phase (4 Weeks)
Participant flow — Induction Phase (4 Weeks)
MilestoneIntranasal Esketamine + Oral Antidepressant
Started779
Completed580
Not completed199
Withdrew: Did not met criteria for op/ma phase84
Withdrew: Adverse event52
Withdrew: Withdrawal by subject22
Withdrew: Lack of efficacy21
Withdrew: Other13
Withdrew: Lost to follow-up5
Withdrew: Protocol violation1
Withdrew: Non-compliance with study drug1
Optimization/Maintenance (48 Weeks)
Participant flow — Optimization/Maintenance (48 Weeks)
MilestoneIntranasal Esketamine + Oral Antidepressant
Started603
Completed150
Not completed453
Withdrew: Study terminated by sponsor331
Withdrew: Withdrawal by subject30
Withdrew: Adverse event25
Withdrew: Lack of efficacy25
Withdrew: Other21
Withdrew: Lost to follow-up10
Withdrew: Protocol violation3
Withdrew: Missed assessment or treatment sessions3
Withdrew: Pregnancy2
Withdrew: Death2
Withdrew: Non-compliance with study drug1
Follow-up Phase (4 Week)
Participant flow — Follow-up Phase (4 Week)
MilestoneIntranasal Esketamine + Oral Antidepressant
Started357
Completed326
Not completed31
Withdrew: Pi decision12
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up5
Withdrew: Adverse event3
Withdrew: Other1

Outcome measures

PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event is any untoward medical occurrence in a clinical study participants who administered a medicinal (investigational or non-investigational) product and does not necessarily have a causal relationship with the treatment. A TEAE defined as an event that was new in onset or increased in severity following treatment initiation.

Time frame:
Up to End of Follow up Phase (Week 56)
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
Percentage of participantsIntranasal Esketamine + Oral Antidepressant
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)90.1
PrimaryPercentage of Participants With Cystitis, Urinary Tract Infections, Renal and Urinary Tract Symptoms, Renal and Urinary Disorders

Percentage of participants with cystitis, urinary tract infections, renal and urinary tract symptoms, renal and urinary disorders were evaluated. Cystitis and urinary tract infections are selected MedDRA preferred terms, "renal and urinary tract symptoms" refers to any preferred term (PT) in the group of selected PTs; and "renal and urinary disorders" refers to a MedDRA System Organ Class (SOC).

Time frame:
Up to End of Follow up Phase (Week 56)
Reported as:
Number · Percentage of participants
Percentage of Participants With Cystitis, Urinary Tract Infections, Renal and Urinary Tract Symptoms, Renal and Urinary Disorders
Percentage of participantsIntranasal Esketamine + Oral Antidepressant
Cystitis0.6
Urinary tract infections8.1
Renal and urinary disorders10.5
Renal and urinary tract symptoms17.0
PrimaryChange From Baseline in Cognitive Test Battery: Detection Test (DET) Score

This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. The DET is a measure of psychomotor function and uses a well-validated simple reaction time. In this outcome measure, speed of performance of participants (calculated as mean of the logarithmic base 10 transformed reaction times) for correct responses was reported. Total score ranges from 2 to 3.3 log 10 milliseconds (msec). Lower score indicates better performance. Higher change from baseline indicates better performance.

Time frame:
Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of Optimization/Maintenance [OP/MA] Phase)
Reported as:
Mean · log10 msec
Change From Baseline in Cognitive Test Battery: Detection Test (DET) Score
log10 msecIntranasal Esketamine + Oral Antidepressant
Change From Baseline in Cognitive Test Battery: Detection Test (DET) Score-0.0028 ± 0.12744
PrimaryChange From Baseline in Cognitive Test Battery: Identification Test (IDN) Score

This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. IDN test is a measure of visual attention (choice reaction time) and scored for speed of response (mean of the log10 transformed reaction times for correct responses). Total score ranges from 2 to 3.3 log 10 msec. Lower score indicates better performance. Higher change from baseline indicates better performance.

Time frame:
Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
Reported as:
Mean · log10 msec
Change From Baseline in Cognitive Test Battery: Identification Test (IDN) Score
log10 msecIntranasal Esketamine + Oral Antidepressant
Change From Baseline in Cognitive Test Battery: Identification Test (IDN) Score-0.0083 ± 0.09656
PrimaryChange From Baseline in Cognitive Test Battery: One Card Learning Test (OCL) Score

This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. OCL test is a measure of visual episodic memory and visual recall test scored using arcsine transformation of the percentage of correct responses (CR). The range for OCL is 0 to 100 percent (%) accuracy; presented as an arcsin transformation, the range is 0 to 1.57. Higher score indicates better performance. Higher change from baseline indicates better performance.

Time frame:
Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
Reported as:
Mean · Arcsine ([sqrt] of proportion of [CR])
Change From Baseline in Cognitive Test Battery: One Card Learning Test (OCL) Score
Arcsine ([sqrt] of proportion of [CR])Intranasal Esketamine + Oral Antidepressant
Change From Baseline in Cognitive Test Battery: One Card Learning Test (OCL) Score0.0502 ± 0.13149
PrimaryChange From Baseline in Cognitive Test Battery: One Back Test (ONB) Score

The ONB is a measure of working memory and scored for speed of correct response (mean of the log10-transformed reaction times for correct responses). Total score ranges from 2 to 3.54 log10 msec. Lower score indicates better performance. Higher change from baseline indicates better performance.

Time frame:
Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
Reported as:
Mean · log10 msec
Change From Baseline in Cognitive Test Battery: One Back Test (ONB) Score
log10 msecIntranasal Esketamine + Oral Antidepressant
Change From Baseline in Cognitive Test Battery: One Back Test (ONB) Score0.0177 ± 0.10026
PrimaryChange From Baseline in Cognitive Test Battery: Groton Maze Learning Test (GMLT) Score

This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. GMLT measures executive function; maze/sequencing test, scored for total number of errors. Total score ranges from 0 to 999 number of errors. Lower score indicates better performance. Higher change from baseline indicates better performance.

Time frame:
Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
Reported as:
Mean · Number of Errors
Change From Baseline in Cognitive Test Battery: Groton Maze Learning Test (GMLT) Score
Number of ErrorsIntranasal Esketamine + Oral Antidepressant
Change From Baseline in Cognitive Test Battery: Groton Maze Learning Test (GMLT) Score6.9 ± 25.36
PrimaryChange From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Total Recall

Hopkins Verbal Learning Test (HVLT) measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition.

Time frame:
Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
Reported as:
Mean · Number correct
Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Total Recall
Number correctIntranasal Esketamine + Oral Antidepressant
Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Total Recall2.8 ± 4.74
PrimaryChange From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Delayed Recall

HVLT measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition.

Time frame:
Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
Reported as:
Mean · Number correct
Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Delayed Recall
Number correctIntranasal Esketamine + Oral Antidepressant
Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Delayed Recall0.8 ± 2.31
PrimaryChange From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Number of Words Recalled

HVLT measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition.

Time frame:
Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
Reported as:
Mean · Number of words recalled
Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Number of Words Recalled
Number of words recalledIntranasal Esketamine + Oral Antidepressant
Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Number of Words Recalled0.3 ± 2.83
PrimaryChange From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Recognition Discrimination Index

HVLT measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition.

Time frame:
Baseline (IND) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
Reported as:
Mean · Number of words
Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Recognition Discrimination Index
Number of wordsIntranasal Esketamine + Oral Antidepressant
Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Recognition Discrimination Index0.5 ± 3.16
SecondaryChange From Baseline to Endpoint in Montgomery Asberg Depression Rating Scale (MADRS) Total Score During Induction (IND) Phase

MADRS measures depression severity, detects changes due to AD treatment. It consists 10 items (evaluate apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts), scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores indicate more severe condition. Negative change in score indicates improvement. Missing data was imputed using last observation carried forward (LOCF) method, last post baseline observation during the phase was carried forward as the "Endpoint".

Time frame:
Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
Reported as:
Mean · Units on a Scale
Change From Baseline to Endpoint in Montgomery Asberg Depression Rating Scale (MADRS) Total Score During Induction (IND) Phase
Units on a ScaleIntranasal Esketamine + Oral Antidepressant
Change From Baseline to Endpoint in Montgomery Asberg Depression Rating Scale (MADRS) Total Score During Induction (IND) Phase-16.4 ± 8.76
SecondaryChange From Baseline to Endpoint in MADRS Total Score During Optimization/Maintenance (OP/MA) Phase

MADRS measure depression severity, detects changes due to AD treatment. It evaluates 10 items: apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

Time frame:
Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA Phase)
Reported as:
Mean · Units on a Scale
Change From Baseline to Endpoint in MADRS Total Score During Optimization/Maintenance (OP/MA) Phase
Units on a ScaleIntranasal Esketamine + Oral Antidepressant
Change From Baseline to Endpoint in MADRS Total Score During Optimization/Maintenance (OP/MA) Phase0.3 ± 8.12
SecondaryChange From Baseline to Endpoint in Patient Health Questionnaire - 9 (PHQ-9) Total Score During IND Phase

PHQ-9 is a 9-item, self-reporting scale assessing depressive symptoms. Each item was rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day), with a total score range of 0-27. A higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), severe (20-27). The recall period is 2 weeks. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

Time frame:
Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
Reported as:
Mean · Unit on a Scale
Change From Baseline to Endpoint in Patient Health Questionnaire - 9 (PHQ-9) Total Score During IND Phase
Unit on a ScaleIntranasal Esketamine + Oral Antidepressant
Change From Baseline to Endpoint in Patient Health Questionnaire - 9 (PHQ-9) Total Score During IND Phase-8.9 ± 6.67
SecondaryChange From Baseline to Endpoint in PHQ-9 Total Score During OP/MA Phase

PHQ-9 is a 9-item, self-reporting scale assessing depressive symptoms. Each item was rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day), with a total score range of 0-27. A higher score indicates greater severity of depression. severity of PHQ-9 categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), severe (20-27). The recall period is 2 weeks. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

Time frame:
Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
Reported as:
Mean · Units on a Scale
Change From Baseline to Endpoint in PHQ-9 Total Score During OP/MA Phase
Units on a ScaleIntranasal Esketamine + Oral Antidepressant
Change From Baseline to Endpoint in PHQ-9 Total Score During OP/MA Phase-0.2 ± 5.65
SecondaryChange From Baseline to Endpoint in Clinical Global Impression of Severity (CGI-S) Scale Score During IND Phase

CGI-S measures severity of participant's illness that include knowledge of participant's history, psychosocial circumstances, symptoms, behavior, impact of symptoms on participant's ability to function. CGI-S evaluates severity of psychopathology on a scale range from 0 - 7, where 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as "Endpoint".

Time frame:
Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
Reported as:
Median · Units on a Scale
Change From Baseline to Endpoint in Clinical Global Impression of Severity (CGI-S) Scale Score During IND Phase
Units on a ScaleIntranasal Esketamine + Oral Antidepressant
Change From Baseline to Endpoint in Clinical Global Impression of Severity (CGI-S) Scale Score During IND Phase-2.0 (-6 to 2)
SecondaryChange From Baseline to Endpoint in CGI-S Scale Score During OP/MA Phase

The CGI-S measures the severity of the participant's illness that include knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7, where 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

Time frame:
Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
Reported as:
Median · Units on a Scale
Change From Baseline to Endpoint in CGI-S Scale Score During OP/MA Phase
Units on a ScaleIntranasal Esketamine + Oral Antidepressant
Change From Baseline to Endpoint in CGI-S Scale Score During OP/MA Phase0.0 (-3 to 4)
SecondaryChange From Baseline to Endpoint in Generalized Anxiety Disorder (GAD-7) Total Score During IND Phase

GAD-7 is brief, validated 7-item self-reported assessment of overall anxiety. Participant's responded to each item using a 4 point scale with response categories: 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield total score ranges from 0 to 21, higher scores indicate more anxiety. Negative change in score indicates improvement. Severity of GAD-7 is categorized as: None (0-4), Mild (5-9), Moderate (10-14), Severe (15 -21). Missing data was imputed using LOCF method, last post baseline observation during the phase was carried forward as "Endpoint".

Time frame:
Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
Reported as:
Mean · Units on a Scale
Change From Baseline to Endpoint in Generalized Anxiety Disorder (GAD-7) Total Score During IND Phase
Units on a ScaleIntranasal Esketamine + Oral Antidepressant
Change From Baseline to Endpoint in Generalized Anxiety Disorder (GAD-7) Total Score During IND Phase-5.9 ± 5.85
SecondaryChange From Baseline to Endpoint in GAD-7 Total Score During OP/MA Phase

GAD-7 is brief and validated 7-item self-reported assessment of overall anxiety. Participants respond to each item using a 4 point scale with response categories: 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score ranges from 0 to 21, higher scores indicate more anxiety. Negative change in score indicates improvement. Severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14), Severe (15 -21). Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

Time frame:
Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
Reported as:
Mean · Units on a Scale
Change From Baseline to Endpoint in GAD-7 Total Score During OP/MA Phase
Units on a ScaleIntranasal Esketamine + Oral Antidepressant
Change From Baseline to Endpoint in GAD-7 Total Score During OP/MA Phase0.2 ± 4.23
SecondaryChange From Baseline to Endpoint in European Quality of Life (EuroQol) 5-Dimension, 5-Level (EQ 5D-5L) During IND Phase: Sum Score

EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a Health Status Index (HSI). HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) \*5. Higher score indicates worst health state.

Time frame:
Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
Reported as:
Mean · Units on a Scale
Change From Baseline to Endpoint in European Quality of Life (EuroQol) 5-Dimension, 5-Level (EQ 5D-5L) During IND Phase: Sum Score
Units on a ScaleIntranasal Esketamine + Oral Antidepressant
Change From Baseline to Endpoint in European Quality of Life (EuroQol) 5-Dimension, 5-Level (EQ 5D-5L) During IND Phase: Sum Score-15.3 ± 16.26
SecondaryChange From Baseline to Endpoint in EQ-5D-5L Score During IND Phase: EQ-VAS

EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine).

Time frame:
Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
Reported as:
Mean · Units on a Scale
Change From Baseline to Endpoint in EQ-5D-5L Score During IND Phase: EQ-VAS
Units on a ScaleIntranasal Esketamine + Oral Antidepressant
Change From Baseline to Endpoint in EQ-5D-5L Score During IND Phase: EQ-VAS17.0 ± 21.69
SecondaryChange From Baseline to Endpoint in EQ-5D-5L Scale Score During IND Phase: Health Status Index

EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a HSI. HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health).

Time frame:
Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
Reported as:
Mean · Units on a Scale
Change From Baseline to Endpoint in EQ-5D-5L Scale Score During IND Phase: Health Status Index
Units on a ScaleIntranasal Esketamine + Oral Antidepressant
Change From Baseline to Endpoint in EQ-5D-5L Scale Score During IND Phase: Health Status Index0.190 ± 0.2138
SecondaryChange From Baseline to Endpoint in European Quality of Life (EuroQol) 5-Dimension, 5-Level (EQ 5D-5L) During OP/MA Phase: Sum Score

EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a Health Status Index (HSI). HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) \*5. Higher score indicates worst health state.

Time frame:
Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
Reported as:
Mean · Units on a Scale
Change From Baseline to Endpoint in European Quality of Life (EuroQol) 5-Dimension, 5-Level (EQ 5D-5L) During OP/MA Phase: Sum Score
Units on a ScaleIntranasal Esketamine + Oral Antidepressant
Change From Baseline to Endpoint in European Quality of Life (EuroQol) 5-Dimension, 5-Level (EQ 5D-5L) During OP/MA Phase: Sum Score-0.7 ± 13.19
SecondaryChange From Baseline to Endpoint in EQ-5D-5L Score During OP/MA Phase: EQ-VAS

EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine).

Time frame:
Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
Reported as:
Mean · Units on a Scale
Change From Baseline to Endpoint in EQ-5D-5L Score During OP/MA Phase: EQ-VAS
Units on a ScaleIntranasal Esketamine + Oral Antidepressant
Change From Baseline to Endpoint in EQ-5D-5L Score During OP/MA Phase: EQ-VAS1.6 ± 18.51
SecondaryChange From Baseline to Endpoint in EQ-5D-5L Scale Score During OP/MA Phase: Health Status Index

EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a HSI. HSI ranges from -0.148 to 0.949 and is anchored at 0 (health state value equal to dead) and 1 (full health).

Time frame:
Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
Reported as:
Mean · Units on a Scale
Change From Baseline to Endpoint in EQ-5D-5L Scale Score During OP/MA Phase: Health Status Index
Units on a ScaleIntranasal Esketamine + Oral Antidepressant
Change From Baseline to Endpoint in EQ-5D-5L Scale Score During OP/MA Phase: Health Status Index-0.009 ± 0.1411
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score During IND Phase

SDS was a 5 item questionnaire used for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, (3) family life/home responsibilities using a 0 to 10 rating scale. Score for the first three items are summed to create a total score of 0 to 30, higher score indicates greater impairment and a negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

Time frame:
Baseline (IND) up to the Endpoint (last post-baseline assessment value during 4 weeks of IND Phase)
Reported as:
Mean · Units on a Scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score During IND Phase
Units on a ScaleIntranasal Esketamine + Oral Antidepressant
Change From Baseline in Sheehan Disability Scale (SDS) Total Score During IND Phase-9.3 ± 7.86
SecondaryChange From Baseline in Sheehan Disability Scale Total Score During OP/MA Phase

SDS was a participant-reported outcome measure and was a 5 item questionnaire used for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0 to 10 rating scale. The score for the first three items are summed to create a total score of 0 to 30 where a higher score indicates greater impairment and a negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

Time frame:
Baseline (OP/MA) up to the Endpoint (last post-baseline assessment value during 52 weeks of OP/MA phase)
Reported as:
Mean · Units on a Scale
Change From Baseline in Sheehan Disability Scale Total Score During OP/MA Phase
Units on a ScaleIntranasal Esketamine + Oral Antidepressant
Change From Baseline in Sheehan Disability Scale Total Score During OP/MA Phase-1.6 ± 8.25
SecondaryPercentage of Participants With Response as Assessed by MADRS Total Score During IND Phase

Response is defined as greater than or equal to (\>=) 50 % reduction from baseline in the MADRS total score. MADRS measures depression severity, detects changes due to AD treatment. It consists 10 items (evaluate apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts), scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores indicate more severe condition. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

Time frame:
Days 8, 15, 22 and Endpoint (last post-baseline assessment during 4 weeks of IND phase)
Reported as:
Number · Percentage of participants
Percentage of Participants With Response as Assessed by MADRS Total Score During IND Phase
Percentage of participantsIntranasal Esketamine + Oral Antidepressant
Day 811.6
Day 1525.0
Day 2242.8
End point78.4
SecondaryPercentage of Participants With Response as Assessed by PHQ-9 Total Score During IND Phase

Response is defined as \>= 50 % reduction from baseline (IND phase) in PHQ-9 total score. PHQ-9 is a 9-item, self-reporting scale assessing depressive symptoms. Each item was rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day), with a total score range of 0-27. The scores are summed for a total score ranging from 0-27. A higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), severe (20-27). The recall period is 2 weeks. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

Time frame:
Day 15 and Endpoint (last post-baseline assessment value during 4 Week IND phase)
Reported as:
Number · Percentage of participants
Percentage of Participants With Response as Assessed by PHQ-9 Total Score During IND Phase
Percentage of participantsIntranasal Esketamine + Oral Antidepressant
Day 1537.2
End point62.0
SecondaryPercentage of Participants With Remission as Assessed by MADRS Total Score During IND Phase

Remission is defined as MADRS total score less than or equal to (\<=) 12. MADRS measures depression severity, detects changes due to AD treatment. It consists 10 items (evaluate apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts), scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores indicate more severe condition. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

Time frame:
Days 8, 15, 22 and Endpoint (last post-baseline assessment value during 4 weeks of IND Phase)
Reported as:
Number · Percentage of participants
Percentage of Participants With Remission as Assessed by MADRS Total Score During IND Phase
Percentage of participantsIntranasal Esketamine + Oral Antidepressant
Day 87.3
Day 1515.6
Day 2227.2
End point47.2
SecondaryPercentage of Participants With Remission as Assessed by PHQ-9 Total Score During IND Phase

Remission is defined as PHQ-9 total score \<= 4. PHQ-9 is a 9-item, self-reporting scale assessing depressive symptoms. Each item was rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day), with a total score range of 0-27. The scores are summed for a total score ranging from 0-27. A higher score indicates greater severity of depression. severity of PHQ-9 categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), severe (20-27). The recall period is 2 weeks. Negative change in score indicates improvement. Missing data was imputed using LOCF method and the last post baseline observation during the phase was carried forward as the "Endpoint".

Time frame:
Day 15 and Endpoint (last post-baseline assessment value during 4 weeks of IND phase)
Reported as:
Number · Percentage of participants
Percentage of Participants With Remission as Assessed by PHQ-9 Total Score During IND Phase
Percentage of participantsIntranasal Esketamine + Oral Antidepressant
Day 1512.7
Endpoint26.9
SecondaryPercentage of Participants With an Increase Score From Predose at Any Time in Clinician-Administered Dissociative States Scale (CADSS) Total Score During IND Phase

The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. It comprises 23 subjective items divided into 3 components: depersonalization (with score range from 0 to 28), derealization (with score range from 0 to 52), and amnesia (with score range from 0 to 8). Participants responses are coded on a 5-point scale (0 = "Not at all", 1 = "Mild", 2 = "Moderate", 3 = 'Severe" and 4 = "Extreme"). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition.

Time frame:
Predose, up to 1.5 hours postdose (up to end of IND phase [Week 4])
Reported as:
Number · Percentage of participants
Percentage of Participants With an Increase Score From Predose at Any Time in Clinician-Administered Dissociative States Scale (CADSS) Total Score During IND Phase
Percentage of participantsIntranasal Esketamine + Oral Antidepressant
Percentage of Participants With an Increase Score From Predose at Any Time in Clinician-Administered Dissociative States Scale (CADSS) Total Score During IND Phase92.0
SecondaryPercentage of Participants With an Increase Score From Predose at Any Time in CADSS Total Score During OP/MA Phase

The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. It comprises 23 subjective items divided into 3 components: depersonalization (with score range from 0 to 28), derealization (with score range from 0 to 52), and amnesia (with score range from 0 to 8). Participants responses are coded on a 5-point scale (0 = "Not at all", 1 = "Mild", 2 = "Moderate", 3 = 'Severe" and 4 = "Extreme"). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition.

Time frame:
Predose, up to 1.5 hours postdose (up to end of OP/MA phase [Week 52])
Reported as:
Number · Percentage of participants
Percentage of Participants With an Increase Score From Predose at Any Time in CADSS Total Score During OP/MA Phase
Percentage of participantsIntranasal Esketamine + Oral Antidepressant
Percentage of Participants With an Increase Score From Predose at Any Time in CADSS Total Score During OP/MA Phase86.1
SecondaryPercentage of Participants With Treatment-Emergent Acute Hypertension (Systolic and Diastolic) During IND and OP/MA Phases

Percentage of participants with treatment-emergent acute hypertension (Systolic Blood Pressure \>=180 millimeters of mercury \[mm Hg\] or Diastolic Blood Pressure \>= 110 mm Hg) during IND and OP/MA Phases were evaluated.

Time frame:
Up to End of OP/MA phase (Week 52)
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment-Emergent Acute Hypertension (Systolic and Diastolic) During IND and OP/MA Phases
Percentage of participantsIntranasal Esketamine + Oral Antidepressant
Systolic BP >=1802.2
Diastolic BP >=1102.4
Acute hypertension4.1

Adverse events

Collected over Up to follow up phase (Week 56). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IND: Intranasal Esketamine + Oral AD0/779 (0%)17/779 (2.2%)587/779 (75.4%)
OP/MA: Intranasal Esketamine + Oral AD2/603 (0.3%)38/603 (6.3%)454/603 (75.3%)
FU: Intranasal Esketamine + Oral AD0/357 (0%)8/357 (2.2%)24/357 (6.7%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventIND: Intranasal Esketamine + Oral ADOP/MA: Intranasal Esketamine + Oral ADFU: Intranasal Esketamine + Oral AD
DepressionPsychiatric disorders5/7793/6035/357
Suicidal IdeationPsychiatric disorders2/7794/6030/357
Suicide AttemptPsychiatric disorders4/7792/6031/357
GastroenteritisInfections and infestations0/7792/6030/357
Hepatitis AlcoholicHepatobiliary disorders0/7790/6031/357
Neoplasm MalignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/7790/6031/357
AnxietyPsychiatric disorders2/7790/6030/357
Cardiac Failure AcuteCardiac disorders0/7791/6030/357
Anal IncontinenceGastrointestinal disorders0/7791/6030/357
Colitis MicroscopicGastrointestinal disorders0/7791/6030/357
Most frequent other events
Showing 10 of 24
Most frequent other events
EventIND: Intranasal Esketamine + Oral ADOP/MA: Intranasal Esketamine + Oral ADFU: Intranasal Esketamine + Oral AD
DizzinessNervous system disorders228/779135/6031/357
DissociationPsychiatric disorders182/779113/6031/357
NauseaGastrointestinal disorders157/77984/6032/357
HeadacheNervous system disorders137/779114/6034/357
SomnolenceNervous system disorders94/77985/6030/357
Viral Upper Respiratory Tract InfectionInfections and infestations19/77970/6031/357
HypoaesthesiaNervous system disorders79/77940/6030/357
DysgeusiaNervous system disorders77/77954/6030/357
VertigoEar and labyrinth disorders68/77943/6031/357
Hypoaesthesia OralGastrointestinal disorders63/77928/6030/357

Baseline characteristics

Age, Continuous
Age, Continuous(years)Intranasal Esketamine + Oral Antidepressant
Mean52.2 ± 13.69
Sex: Female, Male
Sex: Female, Male(Participants)Intranasal Esketamine + Oral Antidepressant
Female502
Male300
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Intranasal Esketamine + Oral Antidepressant
Hispanic or Latino149
Not Hispanic or Latino640
Unknown or Not Reported13
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Intranasal Esketamine + Oral Antidepressant
American Indian or Alaska Native0
Asian81
Native Hawaiian or Other Pacific Islander0
Black or African American15
White686
More than one race8
Unknown or Not Reported12
Region of Enrollment
Region of Enrollment(Participants)Intranasal Esketamine + Oral Antidepressant
ARGENTINA106
AUSTRALIA23
AUSTRIA16
BELGIUM5
BRAZIL52
BULGARIA94
FINLAND2
FRANCE4
GERMANY13
ITALY7
MALAYSIA19
MEXICO10
POLAND6
SOUTH AFRICA64
SOUTH KOREA26
SPAIN42
SWEDEN90
TAIWAN33
TURKEY31
UNITED KINGDOM12
UNITED STATES147
08

Study locations

110 sites
  • New Haven, Connecticut, United States
  • Miami, Florida, United States
  • Marietta, Georgia, United States
  • Iowa City, Iowa, United States
  • Wichita, Kansas, United States
  • Baltimore, Maryland, United States
  • Watertown, Massachusetts, United States
  • Cedarhurst, New York, United States
  • New York, New York, United States
  • Staten Island, New York, United States
  • Cincinnati, Ohio, United States
  • Allentown, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Dallas, Texas, United States
  • Wichita Falls, Texas, United States
  • Richland, Washington, United States
  • Banfield, Argentina
  • Buenos Aires, Argentina
  • Ciudad Autonoma de Buenos Aires, Argentina
  • Cordoba, Argentina
  • La Plata, Argentina
  • Mendoza, Argentina
  • Rosario, Argentina
  • Adelaide, Australia
  • Caulfield, Australia
  • Frankston, Australia
  • Melbourne, Australia
  • Innsbruck, Austria
  • Vienna, Austria
  • Brugge, Belgium
  • Hasselt, Belgium
  • Belo Horizonte, Brazil
  • Fortaleza, Brazil
  • Recife, Brazil
  • Rio de Janeiro, Brazil
  • Santo André, Brazil
  • Sao Jose do Rio Preto, Brazil
  • São Paulo, Brazil
  • Bourgas, Bulgaria
  • Kardzhali, Bulgaria
  • Kazanlak, Bulgaria
  • Pazardzhik, Bulgaria
  • Pleven, Bulgaria
  • Plovdiv, Bulgaria
  • Rousse, Bulgaria
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • Helsinki, Finland
  • Kuopio, Finland
  • Paris, France
  • Poitiers, France
  • Toulon, France
  • TOURS cedex 9, France
  • Berlin, Germany
  • Bochum, Germany
  • Oranienburg-Sachsenhausen, Germany
  • Gwangju, Korea, Republic of
  • Gyeonggi-do, Korea, Republic of
  • Seoul, Korea, Republic of
  • Kaunas, Lithuania
  • Silute, Lithuania
  • Vilnius, Lithuania
  • Ipoh, Malaysia
  • Johor Bahru, Malaysia
  • Kuala Lumpur, Malaysia
  • Acapulco, Mexico
  • Durango, Mexico
  • Mexico City, Mexico
  • Mexico, Mexico
  • Monterrey, Mexico
  • Gdansk, Poland
  • Cape Town, South Africa
  • Garsfontein, South Africa
  • Pretoria, South Africa
  • Badajoz, Spain
  • Bilbao, Spain
  • Madrid, Spain
  • Ourense, Spain
  • Oviedo, Spain
  • Sant Boi de Llobregat, Spain
  • Torrevieja, Spain
  • Valencia, Spain
  • Zamora, Spain
  • Goteborg, Sweden
  • Halmstad, Sweden
  • Lund, Sweden
  • Skovde, Sweden
  • Solna, Sweden
  • Stockholm, Sweden
  • Umea, Sweden
  • Kaohsiung, Taiwan
  • New Taipei City, Taiwan
  • Taichung, Taiwan
  • Tainan, Taiwan
  • Taipei, Taiwan
  • Taoyuan County, Taiwan
  • Ankara, Turkey
  • Bursa, Turkey
  • Gaziantep, Turkey
  • Istanbul, Turkey

Showing the first 100 of 110 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Williamson DJ, Gogate JP, Kern Sliwa JK, Manera LS, Preskorn SH, Winokur A, Starr HL, Daly EJ. Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression. J Clin Psychiatry. 2022 Sep 19;83(6):21m14318. doi: 10.4088/JCP.21m14318. PubMed 36149841 ↗
  • Ochs-Ross R, Wajs E, Daly EJ, Zhang Y, Lane R, Lim P, Drevets WC, Steffens DC, Sanacora G, Jamieson C, Hough D, Manji H, Singh JB. Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study. Am J Geriatr Psychiatry. 2022 May;30(5):541-556. doi: 10.1016/j.jagp.2021.09.014. Epub 2021 Oct 6. PubMed 34750057 ↗
  • Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, George JE, Morrison RL, Sanacora G, Young AH, Kasper S, Sulaiman AH, Li CT, Paik JW, Manji H, Hough D, Grunfeld J, Jeon HJ, Wilkinson ST, Drevets WC, Singh JB. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). J Clin Psychiatry. 2020 Apr 28;81(3):19m12891. doi: 10.4088/JCP.19m12891. PubMed 32316080 ↗
  • Nijs M, Wajs E, Aluisio L, Turkoz I, Daly E, Janik A, Borentain S, Singh JB, DiBernardo A, Wiegand F. Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data. Int J Neuropsychopharmacol. 2020 Jul 29;23(7):426-433. doi: 10.1093/ijnp/pyaa027. PubMed 32270176 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Oct 2017, 24 months.

Results were first posted in Apr 2019, 1 year 6 months after primary completion. A results delay was requested in Oct 2018.

Of 24 phase 3 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2015
First posted
Jul 14, 2015
StartActual
Sep 30, 2015
Primary completionActual
Oct 28, 2017
CompletionActual
Oct 28, 2017
Results delay requested
Oct 24, 2018
Results first posted
Apr 29, 2019
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02497287
Responsible party
Sponsor
First posted
Jul 14, 2015
Start date
Sep 30, 2015
Primary completion
Oct 28, 2017
Completion
Oct 28, 2017
Results posted
Apr 29, 2019
Last update
Apr 29, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion